Lactylation in Desmoplastic Tumours: A Metabolic-Epigenetic Axis Linking Stromal Remodelling, Immune Suppression and Therapy Resistance

Dense extracellular matrix deposition, stromal activation and impaired perfusion can create tumour niches that favour lactate accumulation. Lysine lactylation (Kla) provides a molecular link between lactate metabolism, gene expression and protein function, with potential implications for tumour progression and treatment response. Here, we review histone and non-histone lactylation in desmoplastic and stroma-rich tumour contexts, encompassing pancreatic ductal adenocarcinoma and cholangiocarcinoma alongside selected settings in gastric, colorectal, triple-negative breast and hepatocellular cancers. This framework recognises that stromal features vary within and between these malignancies. We synthesise evidence linking lactylation to cancer stemness, fibroblast activation, stromal remodelling and immune suppression, and examine how these processes contribute to therapeutic resistance. Recurrent mechanisms include metabolic adaptation, enhanced DNA repair, suppression of cell death and impaired antitumour immunity. However, lactylation effects depend on the modified protein, lysine residue and cellular context, and are not uniformly tumour-promoting. We critically assess limitations in chemical discrimination, antibody specificity and causal inference, particularly the difficulty of distinguishing Kla-dependent mechanisms from other effects of lactate metabolism. We also discuss therapeutic strategies targeting lactate availability, lactylation enzymes and individual substrates. Most evidence remains preclinical, highlighting the need for quantitative, site-specific and spatially resolved analyses, functional validation and prospective clinical studies. Establishing which lactylation events directly influence tumour behaviour and treatment response will be essential for translating these findings into selective therapies and clinically informative biomarkers.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-16
DOI
https://doi.org/10.20944/preprints202611.1559.v1
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Lactylation in Desmoplastic Tumours: A Metabolic-Epigenetic Axis Linking Stromal Remodelling, Immune Suppression and Therapy Resistance

Maria Guadalupe Cabral, António Jacinto, Rute M. Salvador, Ines Simoes Gomes et al.
Preprints.org
Cancer, Hypoxia, and Metabolism
preprint

Lactylation in Desmoplastic Tumours: A Metabolic-Epigenetic Axis Linking Stromal Remodelling, Immune Suppression and Therapy Resistance

Maria Guadalupe Cabral, António Jacinto, Rute M. Salvador, Ines Simoes Gomes, Pereira R
preprint en

Abstract

Dense extracellular matrix deposition, stromal activation and impaired perfusion can create tumour niches that favour lactate accumulation. Lysine lactylation (Kla) provides a molecular link between lactate metabolism, gene expression and protein function, with potential implications for tumour progression and treatment response. Here, we review histone and non-histone lactylation in desmoplastic and stroma-rich tumour contexts, encompassing pancreatic ductal adenocarcinoma and cholangiocarcinoma alongside selected settings in gastric, colorectal, triple-negative breast and hepatocellular cancers. This framework recognises that stromal features vary within and between these malignancies. We synthesise evidence linking lactylation to cancer stemness, fibroblast activation, stromal remodelling and immune suppression, and examine how these processes contribute to therapeutic resistance. Recurrent mechanisms include metabolic adaptation, enhanced DNA repair, suppression of cell death and impaired antitumour immunity. However, lactylation effects depend on the modified protein, lysine residue and cellular context, and are not uniformly tumour-promoting. We critically assess limitations in chemical discrimination, antibody specificity and causal inference, particularly the difficulty of distinguishing Kla-dependent mechanisms from other effects of lactate metabolism. We also discuss therapeutic strategies targeting lactate availability, lactylation enzymes and individual substrates. Most evidence remains preclinical, highlighting the need for quantitative, site-specific and spatially resolved analyses, functional validation and prospective clinical studies. Establishing which lactylation events directly influence tumour behaviour and treatment response will be essential for translating these findings into selective therapies and clinically informative biomarkers.

Preprints.org
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon